Eiras, Sonia http://orcid.org/0000-0001-7200-253X
de la Espriella, Rafael
Fu, Xiaoran
Iglesias-Álvarez, Diego
Basdas, Rumeysa
Núñez-Caamaño, J. R.
Martínez-Cereijo, J. M.
Reija, L.
Fernández, A. L.
Sánchez-López, David
Miñana, Gema
Núñez, Julio
González-Juanatey, José R.
Funding for this research was provided by:
ISCIII (PI19/01330)
Consellería de Economía, Emprego e Industria, Xunta de Galicia (IN607B-2022-04)
CIBERCV (CB16/11/0026, CB16/11/00420)
Article History
Received: 31 January 2024
Accepted: 29 May 2024
First Online: 3 July 2024
Declarations
:
: The study complied with the Declaration of Helsinki and was approved by the Galician Clinical Research Ethics Committee (protocol code 2019/439 and 2023/240), and written informed consent was obtained from all participants.
: Not applicable.
: RE reports personal fees from AstraZeneca, Novartis, Boehringer-Ingelheim, and NovoNordisk (outside the submitted work). JN reports personal fees or advisory boards from Alleviant, AstraZeneca, Boehringer Ingelheim, Bayer, Novartis, NovoNordisk, Rovi, and Vifor Pharma (outside the submitted work).